Affibody names Peter Zerhouni CFO

Affibody AB named CBO Peter Zerhouni as CFO in a move that could a signal the Swedish immunology and oncology company is gearing up for an IPO. Zerhouni, who will combine both roles, took InDex Pharmaceuticals Holding AB (SSE:INDEX) public and helped the company raise more than $100 million in financings as the company’s CEO. 

CEO John Fowler and CMO Noreen Roth Henig will depart  Kezar Life Sciences Inc. (NASDAQ:KZR) as part of a restructuring that includes a 41% workforce reduction. Former President and CSO Christopher Kirk, a co-founder and director of the immune-mediated disorder company, will succeed Fowler, who will remain on Kezar’s board. Zung To, SVP, clinical development operations, will lead clinical trial execution and oversee development operations. The restructuring is expected to extend the company’s cash to fund the Phase IIb PALIZADE trial of zetomipzomib to treat lupus nephritis. Top-line data for PALIZADE is expected mid-2026. ...